Lab21 has expanded its range of genetic tests for inherited cardiac syndromes.
The company has added two assays for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and Hypertrophic Cardiomyopathy (HCM) to its range of tests.
CPVT is potentially the most lethal of the inherited cardiac channelopathies, being particularly difficult to diagnose in the absence of genetic testing.
HCM is the most common form of heart muscle disease, affecting one in 500 individuals and is the most common cause of sudden cardiac death in people below the age of 30.
Through its existing UK licence with Pgxhealth, a division of Clinical Data, Lab21 offers exclusive UK and Ireland access to the Familion portfolio of tests for Long QT and Brugada Syndromes.
